Ciaran Hart
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- COVID-19 Clinical Research Studies 6
-
- Frailty in Older Adults 2
- Journals
- The Lancet (6 papers)Annals of Intensive Care (1 paper)BMC Geriatrics (1 paper)Age and Ageing (1 paper)
- Partner nations
- United KingdomSpainNepal
In The Last Decade
Ciaran Hart
9 papers receiving 1.6k citations
Ciaran Hart's Hit Papers
Peers
Comparison fields: 5 of 81
- Infectious Diseases 1.3k
- Applied Microbiology and Biotechnology 35
- Internal Medicine 27
- Geriatrics and Gerontology 24
- Statistics and Probability 45
Countries citing papers authored by Ciaran Hart
This map shows the geographic impact of Ciaran Hart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ciaran Hart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ciaran Hart more than expected).
Fields of papers citing papers by Ciaran Hart
This network shows the impact of papers produced by Ciaran Hart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ciaran Hart. The network helps show where Ciaran Hart may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 7 | 2021 | 37 | |
| 8 | 2021 | 19 | |
| 9 | 2024 | 7 |
About Ciaran Hart
Ciaran Hart is a scholar working on Infectious Diseases, Geriatrics and Gerontology, Epidemiology, Critical Care and Intensive Care Medicine and Public Health, Environmental and Occupational Health, having authored 9 papers that have together received 1.7k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers), Sepsis Diagnosis and Treatment (3 papers), Frailty in Older Adults (2 papers), Palliative Care and End-of-Life Issues (1 paper) and Intensive Care Unit Cognitive Disorders (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (27 citations), Geriatrics and Gerontology (24 citations) and Statistics and Probability (45 citations). Ciaran Hart has collaborated with scholars based in United Kingdom, Spain and Nepal. Their work appears in journals such as The Lancet, Annals of Intensive Care, BMC Geriatrics and Age and Ageing.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.